CoChat
Sign Up
Cited by 1,500Diabetes Treatment and ManagementDiabetes Management and ResearchDiabetes, Cardiovascular Risks, and Lipoproteins

Clinical review of antidiabetic drugs: implications for type 2 diabetes mellitus management

Open access
Chaudhury, Arun, Duvoor, Chitharanjan, Reddy Dendi, Vijaya Sena, Kraleti, Shashank, Chada, Aditya, Ravilla, Rahul, Marco, Asween, Shekhawat, Nawal Singh +8 more·2017·Frontiers in Endocrinology
DOI 10.3389/fendo.2017.00006PMC PMC5256065
Open this paper in CoChat — free accountOpen PDF

Abstract

Type 2 diabetes mellitus (T2DM) is a global pandemic, as evident from the global cartographic picture of diabetes by the International Diabetes Federation (http://www.diabetesatlas.org/). Diabetes mellitus is a chronic, progressive, incompletely understood metabolic condition chiefly characterized by hyperglycemia. Impaired insulin secretion, resistance to tissue actions of insulin, or a combination of both are thought to be the commonest reasons contributing to the pathophysiology of T2DM, a spectrum of disease originally arising from tissue insulin resistance and gradually progressing to a state characterized by complete loss of secretory activity of the beta cells of the pancreas. T2DM is a major contributor to the very large rise in the rate of non-communicable diseases affecting developed as well as developing nations. In this mini review, we endeavor to outline the current management principles, including the spectrum of medications that are currently used for pharmacologic management, for lowering the elevated blood glucose in T2DM.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fendo.2017.00006

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 34

  1. [1]Internal Clinical Guidelines Team. Type 2 Diabetes in Adults: Management. London: National Institute for Health and Care Excellence (2015). 28 p. 26741015
  2. [2]Standards of medical care in diabetes-2016: summary of revisions. Diabetes Care (2016) 39(Suppl 1): S4– 5. 10.2337/dc16-S003 26696680 · DOI
  3. [4]Kalra S Agrawal N. Diabetes and HIV: current understanding and future perspectives. Curr Diab Rep (2013) 13(3): 419– 27. 10.1007/s11892-013-0369-9 23446780 · DOI
  4. [6]Mancia G Preventing new-onset diabetes in thiazide-treated patients. Lancet Diabetes Endocrinol (2016) 4(2): 90– 2. 10.1016/S2213-8587(15)00391-5 26489807 · DOI
  5. [12]Nyenwe EA Kitabchi AE. The evolution of diabetic ketoacidosis: an update of its etiology, pathogenesis and management. Metabolism (2016) 65(4): 507– 21. 10.1016/j.metabol.2015.12.007 26975543 · DOI
  6. [17]American Diabetes Association. Screening for Type 2 Diabetes. (Vol. 18). Clinical Diabetes (2000). Available from: http://journal.diabetes.org/clinicaldiabetes/v18n22000/pg69.htm
  7. [21]Riccardi G Rivellese A. Effects of dietary fiber and carbohydrate on glucose and lipoprotein metabolism in diabetic patients. Diabetes Care (1991) 14(12): 1115– 25. 10.2337/diacare.14.12.1115 1663443 · DOI
  8. [23]Pietraszek A Gregersen S Hermansen K. Alcohol and type 2 diabetes. A review. Nutr Metab Cardiovasc Dis (2010) 20(5): 366– 75. 10.1016/j.numecd.2010.05.001 20556883 · DOI
  9. [24]Defronzo RA Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes (2009) 58(4): 773– 95. 10.2337/db09-9028 19336687 PMC2661582 · DOI · Paper page
  10. [25]Bailey CJ. The current drug treatment landscape for diabetes and perspectives for the future. Clin Pharmacol Ther (2015) 98(2): 170– 84. 10.1002/cpt.144 25963904 · DOI
  11. [26]James JC Andrew SR Charles FS Jr Annie N PA-C diagnosis and management of diabetes: synopsis of the 2016; American Diabetes Association standards of medical care in diabetes. Ann Intern Med (2016) 164: 542– 52. 10.7326/M15-3016 26928912 · DOI
  12. [27]Nathan DM Buse JB Davidson MB Ferrannini E Holman RR Sherwin R Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care (2009) 32(1): 193. 10.2337/dc08-9025 18945920 PMC2606813 · DOI · Paper page
  13. [28]Inzucchi SE Bergenstal RM Buse JB Diamant M Ferrannini E Nauck M Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care (2015) 38(1): 140– 9. 10.2337/dc14-2441 25538310 · DOI · Paper page
  14. [29]Palmer SC Mavridis D Nicolucci A Johnson DW Tonelli M Craig JC Comparison of clinical outcomes and adverse events associated with glucose-lowering drugs in patients with type 2 diabetes: a meta-analysis. JAMA (2016) 316(3): 313– 24. 10.1001/jama.2016.9400 27434443 · DOI
  15. [31]Viollet B Guigas B Garcia N Leclerc J Foretz M Andreelli F Cellular and molecular mechanisms of metfromin: an overview. Clin Sci (Lond) (2012) 122(6): 253– 70. 10.1042/CS20110386 22117616 PMC3398862 · DOI · Paper page
  16. [32]Inzucchi SE Lipska KJ Mayo H Bailey CJ McGuire DK Metformin in patients with type 2 diabetes and kidney disease: a systematic review. JAMA (2014) 312(24): 2668– 75. 10.1001/jama.2014.15298 25536258 PMC4427053 · DOI · Paper page
  17. [33]Fogelman Y Kitai E Blumberg G Golan-Cohen A Rapoport M Carmeli E. Vitamin B12 screening in metformin-treated diabetics in primary care: were elderly patients less likely to be tested? Aging Clin Exp Res (2016). 10.1007/s40520-016-0546-1 26914484 · DOI
  18. [34]Nathan DM Buse JB Kahn SE Krause-Steinrauf H Larkin ME Staten M Rationale and design of the glycemia reduction approaches in diabetes: a comparativeeffectiveness study (GRADE). Diabetes Care (2013) 36(8): 2254– 61. 10.2337/dc13-0356 23690531 PMC3714493 · DOI
  19. [36]Maruthur NM Tseng E Hutfless S Wilson LM Suarez-Cuervo C Berger Z Diabetes medications as monotherapy or metformin-based combination therapy for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med (2016) 164(11): 740– 51. 10.7326/M15-2650 27088241 · DOI · Paper page
  20. [37]Harris KB McCarty DJ. Efficacy and tolerability of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus. Ther Adv Endocrinol Metab (2015) 6(1): 3– 18. 10.1177/2042018814558242 25678952 PMC4321868 · DOI
  21. [38]Riser Taylor S Harris KB. The clinical efficacy and safety of sodium glucose cotransporter-2 inhibitors in adults with type 2diabetes mellitus. Pharmacotherapy (2013) 33(9): 984– 99. 10.1002/phar.1303 23744749 · DOI
  22. [39]UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet (1998) 352(9131): 854– 65; Erratum in: Lancet (1998) 352(9139):1558. 10.1016/S0140-6736(98)07037-8 9742977 · DOI · Paper page
  23. [40]Siraj ES Rubin DJ Riddle MC Miller ME Hsu FC Ismail-Beigi F Insulin dose and cardiovascular mortality in the ACCORD trial. Diabetes Care (2015) 38(11): 2000– 8. 10.2337/dc15-0598 26464212 PMC4876773 · DOI
  24. [41]Ismail-Beigi F. Pathogenesis and glycemic management of type 2 diabetes mellitus: a physiological approach. Arch Iran Med (2012) 15(4): 239– 46. 22424044
  25. [42]Proks P Reimann F Green N Gribble F Ashcroft F Sulfonylurea stimulation of insulin secretion. Diabetes (2002) 51(3): 5368– 76. 10.2337/diabetes.51.2007.S368 12475777 · DOI · Paper page
  26. [43]Al-Arouj M Bouguerra R Buse J Hafez S Hassanein M Ibrahim-Asharaf M Recommendations for management of diabetes during Ramadan. Diabetes Care (2005) 28: 2305– 11. 10.2337/diacare.28.9.2305 16123509 · DOI
  27. [44]Echouffo-Tcheugui JB Dagogo-Jack S Preventing diabetes mellitus in developing countries. Nat Rev Endocrinol (2012) 8(9): 557– 62; Erratum in: Nat Rev Endocrinol (2012) 8(11):692. 10.1038/nrendo.2012.46 22488646 · DOI
  28. [45]Ronacher K Joosten SA van Crevel R Dockrell HM Walzl G Ottenhoff TH. Acquired immunodeficiencies and tuberculosis: focus on HIV/AIDS and diabetes mellitus. Immunol Rev (2015) 264(1): 121– 37. 10.1111/imr.12257 25703556 · DOI
  29. [46]Weyer C Bogardus C Mott DM Pratley RE The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest (1999) 104: 787– 94. 10.1172/JCI7231 10491414 PMC408438 · DOI · Paper page
  30. [47]Garber AJ Abrahamson MJ Barzilay JI Blonde L Bloomgarden ZT Bush MA Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm-2016 executive summary. Endocr Pract (2016) 22(1): 84– 113. 10.4158/EP151126.CS 26731084 · DOI
  31. [48]Ferrannini E DeFronzo RA. Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes. Eur Heart J (2015) 36(34): 2288– 96. 10.1093/eurheartj/ehv239 26063450 · DOI
  32. [49]Evers SS Sandoval DA Seeley RJ. The physiology and molecular underpinnings of the effects of bariatric surgery on obesity and diabetes. Annu Rev Physiol (2016). 27912678
  33. [50]Reilly SM Chiang SH Decker SJ Chang L Uhm M Larsen MJ An inhibitor of the protein kinases TBK1 and IKK-ε improves obesity-related metabolic dysfunctions in mice. Nat Med (2013) 19(3): 313– 21. 10.1038/nm.3082 23396211 PMC3594079 · DOI
  34. [51]Koch L Obesity: teaching an old drug new tricks – amlexanox targets inflammation to improve metabolic dysfunction. Nat Rev Endocrinol (2013) 9(4): 185 10.1038/nrendo.2013.42 23438840 · DOI

Cited by

Sorted by citations

Authors
Chaudhury, A., Duvoor, C., Reddy Dendi, V. S., Kraleti, S., Chada, A., Ravilla, R., Marco, A., Shekhawat, N. S., Montales, M. T., Kuriakose, K., Sasapu, A., Beebe, A., Patil, N., Musham, C. K., Lohani, G. P., & Mirza, W.
Affiliations
  • University of Arkansas Medical Center (US)
  • University of Arkansas at Little Rock (US)
  • Vanderbilt University (US)
  • Arkansas Department of Health (US)
  • CHI St. Vincent (US)
  • The Wright Center for Graduate Medical Education (US)
Corresponding author
  • Chaudhury, Arun
  • Mirza, Wasique
ORCID
Venue
Frontiers in Endocrinology
Publisher
Frontiers Media SA
Published
2017-01-24
Volume
8
Pages
6-6
ISSN
1664-2392 (ISSN-L)
DOI
10.3389/fendo.2017.00006
PMC
PMC5256065
OpenAlex
W2581920297
Cited by
1,500
References
7
Citations by year
2026: 84 · 2025: 163 · 2024: 216 · 2023: 234 · 2022: 203 · 2021: 179 · 2020: 166 · 2019: 142 · 2018: 91 · 2017: 19
FWCI
16.66
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Frontiers in Endocrinology (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
type 2 diabetes, antidiabetic drugs, pharmacological management, hyperglycemia, insulin resistance, beta-cell dysfunction, glycemic control, diabetes pathophysiology

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review